Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 8/20 | 0.49 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA9 | Q16790 | 3/20 | 0.48 |
| ▸ | CA4 | P22748 | 2/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23296124 | 0.84 | CA1 (0.51) | MIFCA1CA2CA9CA4 | |
| SCHEMBL23329310 | 0.84 | CA1 (0.63) | MIFCA1CA2CA9CA4 | |
| SCHEMBL3091122 | 0.82 | MIF (0.53) | MIFCA1CA2CA9CA4 | |
| SCHEMBL23296174 | 0.82 | MIF (0.48) | MIFCA1CA2CA9CA4 | |
| SCHEMBL23296182 | 0.82 | NOTUM (0.53) | MIFCA1CA2CA9CA4 | |
| SCHEMBL23296125 | 0.80 | CA1 (0.57) | CA1CA2CA9CA4NOTUM | |
| SCHEMBL23296178 | 0.80 | NOTUM (0.52) | MIFCA1CA2CA9CA4 | |
| SCHEMBL23329343 | 0.76 | NOTUM (0.47) | MIFCA1CA2CA9CA4 | |
| SCHEMBL23296111 | 0.73 | NOTUM (0.44) | MIFCA1CA2CA9CA4 | |
| SCHEMBL16347647 | 0.71 | MIF (0.50) | MIFCA1CA2CA9NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11214564-B2 | Compounds with thymine skeleton for use in medicine | Technische Universität Dresden (DE) | 2022-01-04 | — | — | US | disclosed |
| EP-3819006-A1 | COMPOUNDS WITH THYMINE SKELETON FOR USE IN MEDICINE | Technische Universität Dresden (DE) | 2021-05-12 | — | — | EP | disclosed |
| US-20210130328-A1 | NOVEL COMPOUNDS WITH THYMINE SKELETON FOR USE IN MEDICINE | Technische Universität Dresden (DE) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130328-A1 | NOVEL COMPOUNDS WITH THYMINE SKELETON FOR USE IN MEDICINE | TMSB10, TMSB4X, TBCA | MIF 1173/4885CA1 4427/4885CA2 4260/4885 |
| US-11214564-B2 | Compounds with thymine skeleton for use in medicine | TMSB10, TMSB4X, TBCA | MIF 1468/4885CA1 4117/4885CA2 3933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.